HWY0304

HWY0304 is a small molecule therapeutic candidate developed by Kanion Pharmaceutical and its subsidiary Huawe Medicine. It is currently in Phase 1 clinical development for the treatment of spasticity and gait disorders associated with various neurological conditions, including stroke, multiple sclerosis, cerebral palsy, and spinal cord injury. HWY0304 acts as an alpha-2 adrenergic receptor agonist, a mechanism that reduces muscle tone by inhibiting the release of excitatory neurotransmitters in the spinal cord. The drug is being developed for oral administration, with the sponsor holding rights for development in China and the United States.